OTCMKTS:ASPHF Ascentage Pharma Group International (ASPHF) Stock Price, News & Analysis $8.48 0.00 (0.00%) As of 05/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About Ascentage Pharma Group International Stock (OTCMKTS:ASPHF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ASPHF alerts:Sign Up Key Stats Today's Range$8.48▼$8.4850-Day Range$8.48▼$8.4852-Week Range$7.50▼$10.65VolumeN/AAverage Volume3,000 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ascentage Pharma Group International (OTCMKTS:ASPHF) is a clinical-stage biopharmaceutical company headquartered in Beijing, China, with a strategic presence in the United States. The company focuses on the discovery and development of targeted small-molecule therapies that modulate programmed cell death, leveraging a deep understanding of the Bcl-2 family of proteins. Ascentage’s core activities center on the research and development of apoptosis regulators, including both Bcl-2 selective and dual Bcl-2/Bcl-xL inhibitors. Its diverse pipeline comprises several compounds in various stages of clinical and preclinical evaluation, addressing both hematological malignancies and solid tumors. The company’s R&D operations integrate proprietary chemistry platforms with translational biology to accelerate the progression of novel candidates through global regulatory pathways. The company serves markets across Greater China, North America, and Singapore, collaborating with contract research organizations and academic institutions worldwide. Through partnerships and strategic alliances, Ascentage aims to expand its clinical footprint and optimize trial execution, particularly for oncology indications with significant unmet medical needs. Founded in 2010 by a team of life science researchers, Ascentage has grown under a management team of industry veterans with extensive experience in drug discovery and development. This leadership combines academic insights with pharmaceutical expertise to drive innovation and establish the company as a global player in oncology therapeutics.AI Generated. May Contain Errors. Read More Receive ASPHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascentage Pharma Group International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASPHF Stock News HeadlinesAscentage Pharma to Present 17 Hematology Clinical Updates at June 2026 EHA CongressMay 13 at 8:50 AM | tipranks.comAscentage Pharma to Highlight Oncology Portfolio at May–June 2026 Investor ConferencesMay 12 at 10:10 AM | tipranks.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.May 14 at 1:00 AM | Profits Run (Ad)Ascentage Pharma Adds Executive Equity Grants to AGM Agenda and Updates Proxy ProcessApril 30, 2026 | tipranks.comAscentage Pharma Sets AGM to Approve 2025 Accounts, Board Mandates and Share Issue AuthorityApril 28, 2026 | tipranks.comAscentage Pharma Group International (AAPG) Releases Q4 2025 Earnings: Revenue Up 162% but Net Loss NarrowsApril 27, 2026 | quiverquant.comQAscentage Pharma to Showcase Six Cancer Drug Studies at 2026 ASCO MeetingApril 21, 2026 | tipranks.comAscentage Pharma Grants New RSUs to Top Executives Under 2022 Incentive SchemeApril 20, 2026 | tipranks.comSee More Headlines ASPHF Stock Analysis - Frequently Asked Questions How have ASPHF shares performed this year? Ascentage Pharma Group International's stock was trading at $8.48 at the beginning of the year. Since then, ASPHF stock has increased by 0.0% and is now trading at $8.48. How do I buy shares of Ascentage Pharma Group International? Shares of ASPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:ASPHF CIKN/A Webwww.ascentagepharma.com Phone86-512-8555-7777FaxN/AEmployees565Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (OTCMKTS:ASPHF) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely, LLC | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredIran War Update: Trump’s Hand-Written Letter Reveals What Comes NextJim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...Paradigm Press | SponsoredMusk's acquisition pattern points to ONE stockMusk needed solar - he acquired SolarCity. Needed data - he bought Twitter. The pattern is clear: when a suppl...Behind the Markets | SponsoredTrump Just Named His Secret AI Project. It's Called "Golden Dawn."Behind a hidden government lab in Tennessee, 40,000 scientists are reportedly finishing work on an AI system d...InvestorPlace | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.